As we continue our exploration of prostate cancer, we turn our focus to one of the earliest areas where medical oncologists are commonly involved: systemic therapy for non-metastatic prostate cancer. In this episode, we will review how to risk stratify localized prostate cancer, differences in FDA-approved prostate-specific PET tracers, how to evaluate for biochemical recurrence following surgical and radiation based treatments for localized prostate cancer, and when to consider utilizing systemic therapy in non-metastatic disease.Content: - A refresher on how we think about systemic treatment options for localized prostate cancer- What role does imaging play? - Definition of biochemical recurrence after upfront surgery vs. radiation - What is castrate-sensitive vs. castrate-resistant disease? - What to do if someone is already on ADT at the time of recurrence? - The fundamental design behind the pivotal STAMPEDE trial and the role it plays in helping us care for our patients with localized prostate cancer ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related